Illustration: Sarah Grillo/Axios

Insurers are trying to figure out ways to help employers afford to cover gene therapies, which can carry price tags in the millions, WSJ reports.

Driving the news: Cigna announced yesterday that it's starting a new program in which employers and insurers will pay monthly for a service that covers gene therapies and review who can get the drugs, which can be dispensed through Cigna's specialty pharmacy.

And CVS, which owns Aetna, said it's going to offer new coverage specifically for gene therapies. Anthem said it's also looking at ways to help employers protect themselves from the cost.

Why it matters: The gene therapy pipeline is robust, and sales are expected to skyrocket in the next few years.

  • Some experts say gene therapies are already too expensive. Insurers want to tie their payments to outcomes, and Cigna hopes to enroll enough patients in the new program to secure better deals.

What they're saying: "Hard to know if the thesis of getting more lives will turn into getting bigger discounts where there is no competition. It clearly has not borne out for those other expensive specialty drugs that lack competition," Memorial Sloan-Kettering Cancer Center's Peter Bach told me.

Yes, but: Many companies already have stop-loss insurance, meaning these additional services could come across as redundant.

  • The 3 insurers included in the Journal's report also operate their own pharmacy benefit managers and specialty pharmacies.
  • Specialty pharmacies owned by the same companies that manage drug benefits have a financial incentive to handle expensive drugs — at a cost to everyone else.

Go deeper:

Go deeper

Wall Street is no longer betting on Trump

Illustration: Sarah Grillo/Axios

Betting markets have turned decisively toward an expected victory for Joe Biden in November — and asset managers at major investment banks are preparing for not only a Biden win, but potentially a Democratic sweep of the Senate and House too.

Why it matters: Wall Street had its chips on a Trump win until recently — even in the midst of the coronavirus-induced recession and Biden's rise in the polls.

With new security law, China outlaws global activism

Illustration: Eniola Odetunde/Axios

The draconian security law that Beijing forced upon Hong Kong last week contains an article making it illegal for anyone in the world to promote democratic reform for Hong Kong.

Why it matters: China has long sought to crush organized dissent abroad through quiet threats and coercion. Now it has codified that practice into law — potentially forcing people and companies around the world to choose between speaking freely and ever stepping foot in Hong Kong again.

53 mins ago - Health

Axios-Ipsos poll: There is no new normal

Data: Axios/Ipsos poll; Chart: Andrew Witherspoon/Axios

The longer the coronavirus pandemic lasts, the farther we're moving apart, according to our analysis of nearly four months of data from the Axios-Ipsos Coronavirus Index.

Why it matters: Ever since life in the U.S. as we knew it came to a screeching halt, we've been trying to get our heads around what a "new normal" will look like. But so far, the politicization of the virus — and our socioeconomic differences — are working against any notion of national unity in impact or response.